Legend Biotech Corporation (LEGN) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Somerset, NJ, United States. Der aktuelle CEO ist Ying Huang.
LEGN hat IPO-Datum 2020-06-05, 2,600 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $3.46B.
Legend Biotech Corporation is a biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other diseases across the United States, China, and international markets. The company's lead product candidate, LCAR-B38M, is a chimeric antigen receptor (CAR-T) therapy designed to treat multiple myeloma, including cases refractory to standard therapies. Legend Biotech's pipeline includes earlier-stage autologous CAR-T candidates in clinical trials for gastric cancer and T-cell lymphoma, as well as additional CAR-T programs targeting CD20, CD22, and CD19 for non-Hodgkin lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. The company is also developing candidates for solid tumors and infectious diseases. Founded in 2014 and based in Somerset, New Jersey, Legend Biotech operates as a subsidiary of Genscript Biotech Corporation and maintains a collaboration and licensing agreement with Janssen Biotech for the development and commercialization of ciltacabtagene autoleucel.
